Apellis Pharmaceuticals, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
APLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Fifth Avenue, Waltham, MA

Insiders trading volume in the past year

Apellis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Morningside Venture Investments Ltd 10%+ Owner $816M Nov 18, 2021
Pascal Deschatelets Chief Scientific Officer $51.1M -$11.9M -18.9% May 20, 2024
Alec Machiels Director $50.2M Jan 1, 2024
Cedric Francois Chief Executive Officer, Director $36.1M -$17.9M -33.1% Nov 1, 2024
Timothy Sullivan Chief Financial Officer $19.1M -$1.15M -5.68% Apr 18, 2024
Adam Townsend Chief Commercial Officer $8.55M -$507K -5.6% Feb 12, 2024
Lukas Scheibler Chief Research Officer $6.96M Dec 1, 2023
David Watson General Counsel $6.6M -$837K -11.3% Dec 11, 2024
Caroline Baumal Chief Medical Officer $6.17M -$165K -2.61% Jan 16, 2024
Federico Grossi Chief Medical Officer $6.04M Jan 5, 2023
Jeffrey Eisele Chief Development Officer $5.63M -$1.04M -15.7% Jan 29, 2024
Nur Nicholson Chief Technical Officer $5.15M -$992K -16.1% Mar 13, 2024
Karen Lewis Chief People Officer $4.68M -$791K -14.5% Jan 29, 2024
Sinclair Dunlop Director $3.33M -$3.86M -53.7% Sep 23, 2024
James Chopas VP/Chief Accounting Officer $2.18M -$166K -7.06% Sep 16, 2024
Mark DeLong Chief Business & Strat Officer $1.82M -$827K -31.3% Aug 12, 2024
Victoria Brown Program Team Lead $1.5M Jan 20, 2023
Paul R. Fonteyne Director $1.43M Jan 1, 2024
Gerald Chan Director $1.11M Jan 1, 2024
Stephanie O'Brien Director $1.11M Jan 1, 2024
Nicole Perry Vice President - Accounting $717K Aug 2, 2021

Recent Insider Transactions by Companies or Individuals for Apellis Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.